The central question the researchers posed was deceptively simple: does the solvent used to extract a seaweed’s chemistry matter? The answer, emphatically, is yes. The team prepared five distinct extracts of H. scoparia using solvents of increasing polarity, n-hexane, dichloromethane, ethanol, methanol and water, and then quantified the total polyphenol, flavonoid and tannin content of each using standardized colorimetric assays. This gradient approach is grounded in a well-established principle of natural products chemistry: polar solvents tend to pull phenolic acids, flavonoid glycosides and tannins out of plant and algal tissue, while nonpolar solvents preferentially dissolve lipids, pigments and terpenoid compounds. By comparing the same biomass extracted five ways, the researchers could effectively partition the alga’s chemical inventory into discrete fractions, each with its own biological signature.

The results confirmed the polarity principle with striking clarity. The aqueous extract, the most polar of the five, registered the highest total polyphenol and tannin contents, and it translated that chemical richness into biological performance, topping the ferric reducing antioxidant power (FRAP) assay, the ABTS radical scavenging assay and the metal-chelating assay. These three tests probe complementary antioxidant mechanisms: FRAP measures the capacity to reduce ferric ions, a proxy for electron-donating ability; ABTS tracks the neutralization of a stable synthetic radical cation; and metal chelation assesses the ability to bind transition metals such as iron and copper that catalyze the formation of destructive hydroxyl radicals through Fenton chemistry. Tannins, with their dense arrays of hydroxyl groups, are particularly effective metal chelators, which helps explain why the tannin-rich aqueous fraction dominated that particular assay.

The methanolic extract told a different but equally instructive story. It achieved the strongest performance in the DPPH assay, which measures scavenging of a lipophilic synthetic radical, and in the CUPRAC assay, which evaluates the reduction of cupric ions. Meanwhile, the dichloromethane extract, the least polar fraction apart from hexane, showed the greatest activity in the phosphomolybdenum assay, a measure of total antioxidant capacity based on the reduction of molybdenum(VI) to molybdenum(V). The fact that no single extract won every contest is not a contradiction but a feature of antioxidant chemistry: different assays respond to different mechanisms, solubilities and reaction kinetics, and a compound that excels at quenching one radical may be mediocre at reducing a metal ion. For bioprospectors, this means the choice of extraction solvent is effectively a choice of which biological activity to prioritize.

Antioxidant capacity was only half of the pharmacological picture. The team also evaluated the extracts’ ability to inhibit two digestive enzymes, alpha-amylase and alpha-glucosidase, that sit at the heart of post-meal glucose spikes. Alpha-amylase cleaves long starch molecules into shorter oligosaccharides in the mouth and small intestine, and alpha-glucosidase then trims those fragments down to absorbable glucose at the intestinal brush border. Drugs that blunt both enzymes, such as acarbose, are standard adjuncts in the management of type 2 diabetes, but they come with gastrointestinal side effects, which has fueled a sustained hunt for gentler plant- and algae-derived inhibitors. Here the ethanolic and dichloromethane extracts stood out, exhibiting dual inhibitory activity against both enzymatic targets, a result the authors highlight as evidence that H. scoparia’s antidiabetic potential is distributed across chemically distinct fractions rather than confined to a single polar class of compounds.

To move beyond crude extracts, the researchers turned to high-performance liquid chromatography (HPLC), which allowed them to tentatively identify individual bioactive compounds within the extracts. Among the molecules flagged by this profiling were sophocarpine, a quinolizidine alkaloid tentatively identified here as an isomer of monocrotaline, and a structurally elaborate phenanthrene carboxylic acid, formally named 1,4a-dimethyl-9-oxo-7-propan-2-yl-3,4,10,10a-tetrahydro-2H-phenanthrene-1-carboxylic acid. The word tentatively matters: HPLC-based identification without full isolation and nuclear magnetic resonance confirmation remains provisional, and the authors are careful to frame their assignments accordingly. Even so, the presence of sophocarpine is particularly noteworthy, because this alkaloid has previously attracted attention in the diabetes literature for its effects on PPAR-gamma-regulated gene expression, a key transcriptional axis in glucose and lipid metabolism.

The study’s most technically ambitious phase was computational. Using molecular docking, the team positioned the tentatively identified compounds inside the three-dimensional active sites of alpha-amylase and alpha-glucosidase, calculating binding affinities and mapping the specific amino acid residues that anchor each ligand. Docking, however, offers only a static snapshot, so the researchers followed up with molecular dynamics simulations, which allow the protein-ligand complexes to flex and breathe in a simulated aqueous environment over time. A ligand that looks perfect in a static dock can fall apart once the enzyme’s loops and side chains begin to move; sustained stability across a dynamics trajectory is therefore a much stronger signal of genuine binding potential. By this combined criterion, sophocarpine and the phenanthrene carboxylic acid emerged as the most promising compounds toward both enzymatic targets, suggesting that the alga’s antidiabetic activity may ultimately trace back to these specific molecules rather than to a diffuse collective effect.

The findings land in a research landscape that has been warming to marine macroalgae as pharmaceutical feedstocks. Previous work on H. scoparia has documented apoptosis-inducing activity in cancer cell lines, antimicrobial effects, antiprotozoal potential and a rich inventory of sulfated polysaccharides, fucoxanthins and mycosporine-like amino acids. A 2024 in vivo study in alloxan-induced diabetic mice had already hinted at the alga’s antihyperglycemic promise. What the new study adds is a rigorous, solvent-resolved map of which chemical fractions carry which activities, plus a computational shortlist of candidate molecules that can now be prioritized for isolation, synthesis and wet-lab validation. It also situates H. scoparia alongside related brown algae, such as Halopithys incurva and Cladostephus spongiosus, that the same Moroccan-Turkish collaboration has recently profiled, building a comparative framework for the region’s phlorotannin-rich seaweed flora.

Significant caveats remain before any of this reaches a pharmacy shelf. In vitro enzyme inhibition does not guarantee clinical efficacy, since intestinal absorption, metabolism and off-target toxicity all intervene between a docking score and a therapeutic effect. The tentative compound identifications require confirmation by isolation and structural elucidation, and the most active extracts will need to be tested in animal models of diabetes and subjected to standard safety pharmacology. Nonetheless, the study makes a persuasive case that a seaweed most people walk past on the beach is a chemically layered resource whose polar fractions deliver antioxidant firepower while its mid-polarity fractions carry dual enzyme-inhibitory activity. As the global burden of type 2 diabetes continues to climb and the search for safer, food-derived enzyme inhibitors intensifies, Halopteris scoparia has earned a place on the shortlist of marine organisms worth watching, and the pipeline from Moroccan tide pools to computational drug design has rarely looked more productive.

Subject of Research: Phytochemical characterization and antioxidant and antidiabetic evaluation of Halopteris scoparia brown alga extracts

Article Title: Exploration of Halopteris scoparia extracts and their bioactive compounds: from phytochemical characterization to in silico investigations

Article References: Aalilou, Y., Zengin, G., Karim, E. M., Hassoun, M., El karfi, W., Moussa, H., Mortada, S., Ak, G., Chtita, S., Ullah, R., Alotaibi, A., Meddah, B., Bouyahya, A., & Faouzi, M. E. A. (2026). Exploration of Halopteris scoparia extracts and their bioactive compounds: from phytochemical characterization to in silico investigations. Plant Biosystems, 160(4), Article 234. https://doi.org/10.1007/s44473-026-00237-y

Image Credits: AI Generated

DOI: 10.1007/s44473-026-00237-y

Keywords: Halopteris scoparia, brown algae, antioxidant, antidiabetic, alpha-amylase, alpha-glucosidase, polyphenols, tannins, sophocarpine, molecular docking, molecular dynamics, marine natural products

Subretinal fibrosis is the body’s wound-healing response gone awry in the confined space between the retinal pigment epithelium and the photoreceptors. When abnormal choroidal blood vessels invade the subretinal space in neovascular AMD, bleeding, inflammation and vascular endothelial growth factor–driven remodeling follow. The retinal pigment epithelial (RPE) cells that normally act as quiet, polarized guardians of the photoreceptor layer respond by abandoning their identity: they lose tight junctions, reorganize their cytoskeleton, and transform into migratory, contractile, matrix-secreting cells. This process, epithelial-mesenchymal transition, or EMT, is driven centrally by transforming growth factor-beta (TGF-β) signaling and produces the collagen-rich scar that physically distorts and eventually destroys the overlying retina.

The research team, led by corresponding authors Chaoyang Zhang, Xiufeng Zhong, Haibin Tian and Jingfa Zhang, with first authors Xi Wang and Xueying Wang, reasoned that a molecule already known to suppress fibrosis in other organs could be repurposed for the eye. Sophocarpine has previously shown anti-fibrotic activity in hepatic and pulmonary models, and its alkaloid chemistry suggested a small molecule capable of crossing biological membranes and reaching intracellular targets. What remained entirely unknown was whether it could do anything for ocular fibrosis—and whether it could do so without harming the delicate neural retina it would have to coexist with.

The safety question came first, and the answer was reassuring. The investigators injected sophocarpine intravitreally into C57BL/6J mice at a concentration of 200 micromolar and then interrogated retinal function with electroretinography, a technique that measures the summed electrical responses of photoreceptors and inner retinal neurons to light flashes. Histological examination of the treated retinas found no detectable acute toxicity. That combination—a preserved electroretinographic waveform and an intact retinal architecture—is the basic license a compound needs before it can be considered seriously for intravitreal delivery, and many candidates never clear that bar.

With safety established, the team moved to a disease model that has become the standard for studying the fibrotic sequelae of neovascular AMD: laser-induced choroidal neovascularization. Focused laser burns to the mouse Bruch’s membrane trigger the growth of abnormal choroidal vessels into the subretinal space, followed by fibrotic scarring that closely mirrors the human lesion. When sophocarpine was delivered into the eyes of these mice, the CNV lesions shrank measurably, collagen deposition within the lesions decreased, and—critically—the co-localization of alpha-smooth muscle actin with RPE65, a marker of RPE cells that had acquired myofibroblast characteristics, was reduced. In plain terms, the RPE cells at the lesion edge were less inclined to become scar-forming cells.

The cellular mechanism was then dissected in culture using two complementary human RPE systems: the widely used ARPE-19 cell line and induced pluripotent stem cell–derived RPE cells, which recapitulate native RPE biology more faithfully. When these cells were stimulated with TGF-β1, they predictably ramped up the mesenchymal program: fibronectin, alpha-smooth muscle actin and vimentin all rose, while the tight-junction protein ZO-1, a hallmark of the healthy epithelial state, was lost. Sophocarpine treatment reversed this cascade. It suppressed the induction of fibronectin, α-SMA and vimentin, preserved ZO-1 expression, and curtailed the functional consequences of EMT—cell migration measured in wound-healing and Transwell assays, and the contractile behavior that scars use to wrinkle and detach the retina, captured in gel contraction assays. The findings were confirmed at transcript, protein and cellular localization levels using quantitative PCR, Western blotting and immunofluorescence.

The mechanistic heart of the paper lies in a striking signaling selectivity. TGF-β signals through two major intracellular routes: the canonical Smad pathway, in which Smad2 and Smad3 transcription factors are phosphorylated and carry the signal to the nucleus, and the non-canonical MAPK pathways, including the MEK/ERK cascade and p38 MAPK. Sophocarpine preferentially reduced the phosphorylation of MEK, ERK and p38 while leaving Smad2/3 phosphorylation untouched. This dissociation is significant because it suggests the compound does not blunt TGF-β signaling wholesale—which could interfere with the many homeostatic roles TGF-β plays in the eye—but instead specifically interrupts the MAPK arm that drives EMT-associated proliferation, migration and matrix production.

To probe how sophocarpine might achieve that selectivity at the molecular level, the team turned to computational structural biology. Molecular docking predicted that the alkaloid fits into binding pockets on MEK1, MEK2 and ERK2, the kinase pair that constitutes the canonical MAPK relay, and molecular dynamics simulations suggested the docked complexes remain stable over simulated time. These are predictive, not definitive, results—binding in silico must ultimately be validated with direct biophysical measurements and target-engagement assays in cells—but they furnish a concrete, testable hypothesis: that sophocarpine acts as a direct inhibitor of upstream MAPK kinases, thereby explaining both the reduced ERK and p38 phosphorylation and the suppression of the EMT program downstream.

The translational implications are considerable. Anti-VEGF therapy, the current mainstay for neovascular AMD, suppresses vascular leakage and growth but does nothing to stop the fibrovascular scar once it begins to organize; a substantial fraction of treated patients develop subretinal fibrosis and irreversible vision loss despite flushes of injections. A molecule that targets the fibrotic arm of the disease—by preserving RPE identity and restraining the TGF-β–MAPK–EMT axis—would address a therapeutic void that no approved drug currently fills. It would also be an unusually accessible candidate: sophocarpine is a defined small molecule with a long history of human exposure in herbal preparations, which could streamline preclinical development compared with entirely novel chemical entities.

That said, the distance from a laser-burn mouse and a culture dish to a clinic-ready therapy remains long. The study used a single dose level for the intravitreal safety assessment, relied on an acute injury model rather than spontaneous, slowly evolving human fibrosis, and its mechanistic target hypothesis awaits confirmation with techniques such as surface plasmon resonance and kinase assays. The authors themselves position sophocarpine as a promising preclinical candidate that warrants further investigation. Even so, the convergence of findings—in vivo reduction of scarring, in vitro reversal of EMT, and a coherent signaling rationale—makes this one of the more complete early-stage stories in ocular fibrosis research, and a reminder that some of ophthalmology’s next tools may still come from plants that traditional medicine has used for centuries.

Subject of Research: Therapeutic inhibition of subretinal fibrosis and retinal pigment epithelial EMT by the plant-derived alkaloid sophocarpine

Article Title: Sophocarpine, a bioactive alkaloid derived from Sophora flavescens, alleviates subretinal fibrosis by suppressing epithelial-mesenchymal transition

Article References: Sophocarpine, a bioactive alkaloid derived from Sophora flavescens, alleviates subretinal fibrosis by suppressing epithelial-mesenchymal transition. (n.d.). https://doi.org/10.1186/s12967-026-08995-1

Image Credits: AI Generated

DOI: 10.1186/s12967-026-08995-1

Keywords: sophocarpine, Sophora flavescens, subretinal fibrosis, neovascular age-related macular degeneration, retinal pigment epithelium, epithelial-mesenchymal transition, TGF-beta, MEK/ERK, p38 MAPK, choroidal neovascularization, anti-fibrotic therapy, Journal of Translational Medicine